[Version 8.2,01/2021]

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HIPRABOVIS BALANCE lyophilisate and suspension for suspension for injection for bovine

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (3 ml) contains:

Active substances:
Lyophilisate fraction:
Bovine respiratory syncytial virus, attenuated, strain Lym-56 …….....≥ 10^4 $CCID_{50}$*
* $CCID_{50}$: Cell culture infective dose 50%

Liquid fraction:
Parainfluenza-3 virus, inactivated, strain SF4 …….....…….... HAI* ≥ 16
Bovine viral diarrhoea virus, inactivated, strain NADL ……..……..... SN** ≥ 20
* HAI: mean haemagglutination inhibition titre induced in rabbits (≥ 480 HAU before inactivation)
** SN: mean serum neutralisation titre induced in rabbits. (≥ 10^6 $CCID_{50}$ before inactivation)

Adjuvant:
Aluminium hydroxide (Al^{3+})..... 6.34 mg

Excipients
Thimerosal (preservative) ..... 0.3 mg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Lyophilisate and suspension for suspension for injection.
The lyophilisate is a yellowish tablet.
The suspension is a pinkish liquid.

4. CLINICAL PARTICULARS

4.1 Target species

Bovine (cows, heifers and calves).

4.2 Indications for use, specifying the target species

Cows and heifers: Prevention of bovine viral Diarrhoea (including Mucosa Disease) (BVD).

Calves: Prevention of Parainfluenza 3 (PI3), Mucosa Disease or Bovine Viral Diarrhoea (BVD) and of Pneumonia caused by Bovine Respiratory Syncytial virus (BRS).

Immunity starts 3 weeks after the first administration and lasts 12 months.

4.3 Contraindications

None.

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals

Vaccinate only healthy animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-administration, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

An anaphylactic reaction may occur very rarely in a sensitized animal. In this case, appropriate treatment, using antihistamines, epinephrine, or a similar drug, is recommended.

Hypersensitivity reactions, including anaphylaxis (which may be fatal) have been reported rarely. In such cases, an appropriate symptomatic treatment should be administered.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product needs to be made on a case-by-case basis.

4.9 Amounts to be administered and administration route

Bovine: administer one dose (3 ml) as of 4 weeks of age.

Resuspend the lyophilised fraction with the liquid fraction and shake before using.
Administer the vaccine when it is at ambient temperature, between +15 and +25ºC.

The administration method is by intramuscular injection in the neck muscles, or subcutaneous in the dewlap.

Recommended vaccinal schedule:

Calves:
Primary vaccination: administer one dose. It is advisable to administer a second dose at 21-30 days, especially if very young animals are vaccinated.
Revaccination: one vaccination every 12 months.

Cows:
Primary vaccination: administer one dose, followed by a second dose at 21-30 days.
Revaccination: one vaccination every 12 months.

Heifers:
Primary vaccination: administer one dose, followed by a second dose at 21-30 days, a month before the first mating.
Revaccination: one vaccination every 12 months.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Adverse reactions other than those already mentioned under section 4.6, observed after the administration of 10 doses of vaccine, are not expected.

4.11 Withdrawal period(s)

Zero days

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: live and inactivated viral vaccines for the bovine species.
ATCvet code: QI02AH.
To stimulate active immunity against the BVD, PI-3 and BRS viruses in order to prevent bovine respiratory syndrome and reproductive failure associated with the BVD virus.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Liquid fraction:
Aluminium hydroxide
Dimethicone
Thimerosal
Water for injections

Lyofilisated fraction:
Disodium phosphate dodecahydrate
Potassium dihydrogen phosphate
Gelatine
Sodium chloride
Sucrose
Monosodium glutamate
Sodium chloride

6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 18 months.
Shelf-life after dilution or reconstitution according to directions: 3 hours.

6.4. Special precautions for storage

Store and transport refrigerated (between 2 ºC and 8 ºC).
Protect from light.
Do not freeze.

6.5 Nature and composition of immediate packaging

Liquid fraction: the container is composed of Type I, 20-ml, amber coloured glass vials with 15 ml (5 doses) (in accordance with the current edition of the Ph.Eur), 100-ml amber coloured glass flasks with 90 ml (25 and 30 doses) and Type II 250 ml with 240 ml (80 doses) (in accordance with the current edition of the Ph.Eur), with their corresponding bromobutyl elastomer closures classified as Type I (in accordance with the current edition of the Ph.Eur), and anodized aluminium caps.

Lyophilised fraction: the container is composed of Type I, colourless, 10-ml (5, 25, 30 and 80 doses), glass vials (in accordance with current edition of the Ph.Eur), bromobutyl elastomer closures classified as Type I (in accordance with the current edition of the Ph.Eur), and anodized aluminium caps.

Pack sizes:
-Box with 1 vial of lyophilised fraction (5 doses) + one 20-ml vial of liquid fraction (with 15 ml).
-Box with 1 vial lyophilised fraction (25 doses) + one 100-ml vial of liquid fraction (with 75 ml)
-Box with 1 vial lyophilised fraction (30 doses) + one 100-ml vial of liquid fraction (with 90 ml).
-Box with 1 vial lyophilised fraction (80 doses) + one 250-ml vial of liquid fraction (with 240 ml).

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170- Amer (Girona) Spain

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10 DATE OF REVISION OF THE TEXT

PROHIBITION OF SALE, SUPPLY AND/OR USE

For animal treatment only. Medicine subject to a veterinary prescription.
Administration under control or supervision of the veterinarian.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

LABEL OF THE LIQUID FRACTION OF 5 DOSES – 20-ml glass vial
5 doses (15 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HIPRABOVIS BALANCE liquid fraction

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Each dose (3ml) contains:
Parainfluenza-3 virus, inactivated, strain SF4: HAI ≥ 16, Bovine viral diarrhoea virus, inactivated, strain NADL: SN ≥ 20, Adjuvant – Aluminium hydroxide (Al^{3+}): 6.34 mg; Thimerosal (Preservative): 0.3 mg

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

5 doses (15 ml).

4. ROUTE(S) OF ADMINISTRATION

Intramuscular or subcutaneous route.

5. WITHDRAWAL PERIOD(S)

Withdrawal period(s): Zero days.

6. BATCH NUMBER

Batch {number}

7. EXPIRY DATE

EXP: {month/year}
Once reconstituted, use within a 3-hour period.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

LIQUID FOR 25 DOSES (100-ml BOTTLE) / 30 DOSES (100-ml BOTTLE) / 80 DOSES (250-ml BOTTLE)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HIPRABOVIS BALANCE liquid fraction.

2. STATEMENT OF ACTIVE SUBSTANCES

Each dose (3 ml) contains:

Active substances:
Liquid fraction:
Parainfluenza-3 virus, inactivated, strain SF4 ……..…… HAI ≥ 16*
Bovine viral diarrhoea virus, inactivated, strain NADL ……..…….... SN ≥ 20**
* HAI: mean haemagglutination inhibition infective titre induced in rabbits. (≥ 480 HAU before inactivation)

** SN: mean serum neutralisation titre induced in rabbits. (≥ 10^6 $CCID_{50}$ before inactivation)

Adjuvant:
Aluminium hydroxide (Al^{3+})..... 6.34 mg

Excipient.
Thimerosal (preservative)….....0.3 mg

3. PHARMACEUTICAL FORM

Liquid fraction.

4. PACKAGE SIZE

25 doses (75 ml)
30 doses (90 ml).
80 doses (240 ml).

5. TARGET SPECIES

Bovine (cows, heifers and calves).

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Dose: 3 ml / animal.
Resuspend the lyophilised fraction with the liquid fraction and shake before use.
Administer the vaccine when at ambient temperature, between +15 and +25ºC.

Route of administration: intramuscular, in the neck muscles, or subcutaneous in the dewlap.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s): Zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.
Accidental self-injection is dangerous.

10. EXPIRY DATE

EXP: {month/year}

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 ºC and 8 ºC). Protect from light. Do not freeze.
Once reconstituted, use within a 3-hour period.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. The vaccine to be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Laboratorios Hipra, S.A.
Avda. La Selva, 135
17170 Amer (Girona)
SPAIN

16. MARKETING AUTHORISATION NUMBER(S)

17. MANUFACTURER'S BATCH NUMBER

Batch {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

LABEL OF THE LYOPHILISED FRACTION
5 doses/ 25 doses / 30 doses/ 80 doses

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HIPRABOVIS BALANCE lyophilised fraction

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Each dose (3 ml) contains:
Bovine respiratory syncytial virus, strain Lym-56 attenuated …..... $\geq 10^4$ $CCID_{50}$*
*$CCID_{50}$: cell culture infective dose 50%

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

5 doses
25 doses
30 doses
80 doses

4. ROUTE(S) OF ADMINISTRATION

Intramuscular or subcutaneous route.

5. WITHDRAWAL PERIOD(S)

Withdrawal period(s): Zero days.

6. BATCH NUMBER

Batch {number}.

7. EXPIRY DATE

EXP: {month/year}
Once reconstituted, use within a 3-hour period.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARBOARD BOX
5 doses/ 25 doses/ 30 doses/ 80 doses (1 vial lyophilised fraction + 1 vial liquid fraction)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HIPRABOVIS BALANCE lyophilisate and suspension for preparation of suspension for injection for bovine

2. STATEMENT OF ACTIVE SUBSTANCES

Each dose (3 ml) contains:

Active substances:
Lyophilisate fraction:
Bovine respiratory syncytial virus, attenuated, strain Lym-56 …..……..…..…....≥ 10^4 $CCID_{50}$*

* $CCID_{50}$: Cell culture infective dose 50%

Liquid fraction:
Parainfluenza-3 virus, inactivated, strain SF4 ……...…….....……..… HAI* ≥ 16
Bovine viral diarrhoea virus, inactivated, strain NADL ……..…….....…….. SN** ≥ 20

* HAI: mean haemagglutination inhibition titre induced in rabbits. (≥ 480 HAU before inactivation)
** SN: mean serum neutralisation titre induced in rabbits. (≥ 10^6 $CCID_{50}$ before inactivation)

Adjuvants:
Aluminium hydroxide (Al^{3+})..... 6.34 mg

Excipient:
Thimerosal (preservative)…….....……0.3 mg

3. PHARMACEUTICAL FORM

Lyophilisate and suspension for suspension for injection.

4. PACKAGE SIZE

1 vial of lyophilised fraction (10 ml) and 1 vial of 20 ml of liquid fraction (5 doses)
1 vial of lyophilised fraction (10 ml) and 1 vial of 75 ml of liquid fraction (25 doses)
1 vial of lyophilised fraction (10 ml) and 1 vial of 100 ml of liquid fraction (30 doses)
1 vial of lyophilised fraction (10 ml) and 1 vial of 250 ml of liquid fraction (80 doses)

5. TARGET SPECIES

Bovine (cows, heifers and calves).

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Dose: 3 ml / animal.
Resuspend the lyophilised fraction with the liquid fraction and shake before use.
Administer the vaccine when at ambient temperature, between +15 and +25ºC.

Route of administration: intramuscular, in the neck muscles, or subcutaneous in the dewlap.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s): Zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.
Accidental self-injection is dangerous.

10. EXPIRY DATE

EXP: {month/year}

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (between 2 ºC and 8 ºC). Protect from light. Do not freeze.
Once reconstituted, use within a 3-hour period.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. The vaccine is to be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN

16. MARKETING AUTHORISATION NUMBER(S)

---

17. MANUFACTURER'S BATCH NUMBER

Batch {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET:
HIPRABOVIS BALANCE lyophilisate and suspension for suspension for injection for bovine

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:

Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170 Amer (Girona) Spain
Tel. +34 972 43 06 60
Fax. +34 972 43 06 61
E-mail: hipra@hipra.com

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

HIPRABOVIS BALANCE lyophilisate and suspension for suspension for injection for bovine

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each dose (3 ml) contains:

Active substances:
Lyophilisate fraction:
Bovine respiratory syncytial virus, attenuated, strain Lym-56 …….....≥ 10^4 $CCID_{50}$*
* $CCID_{50}$: Cell culture infective dose 50%

Liquid fraction:
Parainfluenza-3 virus, inactivated, strain SF4 ……..……..…….....……..… HAI* ≥ 16
Bovine viral diarrhoea virus, inactivated, strain NADL ……..……..... SN** ≥ 20

* HAI: mean haemagglutination inhibition titre induced in rabbits (≥ 480 HAU before inactivation)
** SN: mean serum neutralisation titre induced in rabbits. (≥ 10^6 $CCID_{50}$ before inactivation)

Adjuvant:
Aluminium hydroxide (Al^{3+})..... 6.34 mg

Excipient:
Thimerosal (preservative) ..... 0.3 mg

Lyophilisate and solvent for preparation for suspension for injection.
The lyophilisate is a yellowish tablet.
The suspension is a pinkish liquid.

4. INDICATION(S)

Cows and heifers: Prevention of bovine viral Diarrhoea (including Mucosa Disease) (BVD).

Calves: Prevention of Parainfluenza 3 (PI3), Mucosa Disease or Bovine Viral Diarrhoea (BVD) and of pneumonia caused by Bovine Respiratory Syncytial virus (BRS).

Immunity starts 3 weeks after the first administration and lasts 12 months.

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

An anaphylactic reaction may occur very rarely in a sensitized animal. In this case, appropriate treatment, using antihistamines, epinephrine, or a similar drug, is recommended.

Hypersensitivity reactions, including anaphylaxis, a severe form of allergic reaction which may be fatal, have been reported rarely. In such cases, an appropriate symptomatic treatment should be administered.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Bovine (cows, heifers and calves).

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Bovine: administer one dose (3 ml), as of eight weeks of age.

The administration method is by intramuscular injection in the neck muscles, or subcutaneous in the dewlap.

Recommended vaccinal schedule:

Calves:
Primary vaccination: administer one dose. It is advisable to administer a second dose at 21-30 days, especially if very young animals are vaccinated.
Revaccination: one vaccination every 12 months.

Cows:
Primary vaccination: administer one dose, followed by a second dose at 21-30 days.
Revaccination: one vaccination every 12 months.

Heifers:
Primary vaccination: administer one dose, followed by a second dose at 21-30 days, a month before the first mating.
Revaccination: one vaccination every 12 months.

9. ADVICE ON CORRECT ADMINISTRATION

Resuspend the lyophilised fraction with the liquid fraction and shake before using.
Administer the vaccine when it is at ambient temperature, between +15 and +25ºC.
Once reconstituted, use within a 3-hour period.

10. WITHDRAWAL PERIOD(S)

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Store and transport refrigerated (2 ºC and 8 ºC). Do not freeze.
Store the container in the outer packaging to protect it from light.
Do not use after the date of expiry that appears on the label/box after EXP.

12. SPECIAL WARNING(S)

Special precautions for use in animals
Vaccinate only healthy animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-administration, seek medical advice immediately and show the package leaflet or the label to the physician.

Use during pregnancy, lactation or lay
Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product needs to be made on a case-by-case basis.

Overdose (symptoms, emergency procedures, antidotes), if necessary:
Adverse reactions other than those already mentioned under “Adverse reactions”, observed after the administration of 10 doses of vaccine, are not expected.

Incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

---

15. OTHER INFORMATION

Pack sizes:
Box with 1 vial of lyophilised fraction (5 doses) + one 20-ml vial of liquid fraction (with 15 ml).
Box with 1 vial lyophilised fraction (25 doses) + one 100-ml vial of liquid fraction (with 75 ml)
Box with 1 vial lyophilised fraction (30 doses) + one 100-ml vial of liquid fraction (with 90 ml).
Box with 1 vial lyophilised fraction (80 doses) + one 250-ml vial of liquid fraction (with 240 ml).

Not all pack sizes may be marketed.

For animal treatment only. Medicine subject to a veterinary prescription.
Administration under control or supervision of the veterinarian.